Subclinical atrial fibrillation detected by devices is associated with increased stroke risk, but evidence regarding the efficacy of long-term anticoagulation in these patients remains uncertain.
Does anticoagulation reduce stroke risk in patients with subclinical atrial fibrillation detected by devices?
This AHA scientific statement highlights the knowledge gaps in managing subclinical atrial fibrillation detected by devices, particularly regarding the role of long-term anticoagulation for stroke prevention.
The widespread use of cardiac implantable electronic devices and wearable monitors has led to the detection of subclinical atrial fibrillation in a substantial proportion of patients. There is evidence that these asymptomatic arrhythmias are associated with increased risk of stroke. Thus, detection of subclinical atrial fibrillation may offer an opportunity to reduce stroke risk by initiating anticoagulation. However, it is unknown whether long-term anticoagulation is warranted and in what populations. This scientific statement explores the existing data on the prevalence, clinical significance, and management of subclinical atrial fibrillation and identifies current gaps in knowledge and areas of controversy and consensus.
Noseworthy et al. (Thu,) conducted a review in Subclinical atrial fibrillation. Anticoagulation was evaluated. Subclinical atrial fibrillation detected by devices is associated with increased stroke risk, but evidence regarding the efficacy of long-term anticoagulation in these patients remains uncertain.